Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Akebia Therapeutics (Cincinnati, OH) a preclinical-stage small molecule company focused on anemia, vascular disorders and angiogenesis, closed a $4.1M Series B financing. Participants include Novartis Bioventures, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem Venture Fund.

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

Akebia Therapeutics (Cincinnati, OH) a clinical-stage pharmaceutical focused on anemia and vascular disorders, closed a $22M Series B financing. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem.

FerroKin Biosciences (San Carlos, CA) a preclinical-stage biopharmaceutical company focused on iron chelator for treatment of anemia, closed a $12M Series B financing. Participants include Clarus Ventures, Burrill & Co., Celegene, MP Healthcare Venture Management and Healthcap Ventures.

Akebia Therapeutics (Cincinnati, OH) a clinical-stage biopharmaceutical company focused on the development of small-molecules for anemia and vascular disease, closed a $16M Series A bringing the total financing to $25M. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital.

FerroKin Biosciences (San Carlos, CA) early-stage developer of iron chelator for treatment of anemias, closed a $15M Series A financing. Participants include Clarus Ventures, Burrill & Co. and Celegene Inc.

  

to top of page...